// App-Quantinova.ai

e16080 : A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Researchers

Presenter

  • Edwin M. Posadas

Principal Investigators

  • Mourad Tighgohart

  • YI-TSUNG LU

  • Neil Bhowmick

  • Andre Rogatko

  • Hsian-Rong Tseng

  • Leland WK Chung

  • Leland Green

  • Margarit Sievert

  • Amy Oppenheim

  • Nancy P. Moldawer

  • Beatrice Knudsen

  • Michael Freeman

Medical Centers

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Department of Molecular and Medical Pharmocology, University of California, Los Angeles, Los Angeles, CASamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Cabozantinib

Outcome

  • Positive

Study Design

  • single arm

Phase

  • II

Study Id's

  • NCT01834651

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved